Antiviral therapy of hepatitis C in 2014: do we need resistance testing? | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing?. Antiviral Res. 2014;105:64-71.

Publication Type:

Journal Article

Authors:

Schneider, M.D.; Sarrazin, C.

Source:

Antiviral Res, Volume 105, p.64-71 (2014)

Keywords:

analysis, boceprevir, CLASS, Genotype, Germany, HCV, hepatitis, Hepatitis C, Internal Medicine, Life, Medicine, Mutation, PART, Patients, protease inhibitor, Protease Inhibitors, Research, resistance, Retreatment, Sequence Analysis, simeprevir, sofosbuvir, SVR, Telaprevir, testing, therapy, Time, treatment, Treatment Failure

Cited On:

Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/24583028

Export Citation:

RIS Format

Top